Lenvatinib: tested in a combination
307 studies: another drug in the study is under test too. Page 3 of 4. Open to participants first (149), then studies with results posted, then the rest; newest registration first within each.
- Tislelizumab Plus TKI as Adjuvant Therapy Versus Active Surveillance in Patients With HCCStatus unknownNCT06059885Phase 2Report a problem
- Cadonilimab (AK104) Plus Lenvatinib in Previously Immunotherapy-Treated Advanced/Metastatic Clear Cell Renal Cell CarcinomaActive, not recruitingNCT06035224Phase 2Report a problem
- Lenvatinib, Pembrolizumab, and Tumor Treating Fields (TTFields) for Second-line Treatment of GlioblastomaWithdrawnNCT05973903Phase 1/2Report a problem
- A Study to Evaluate Efficacy and Safety of Lenvatinib Combined With Tislelizumab in Patients With FHRCCCompletedNCT05877820Phase 2Report a problem
- Pembrolizumab Plus Lenvatinib in Previously Treated Classic Kaposi SarcomaWithdrawnNCT05846724Phase 2Report a problem
- Study of Cadonilimab (AK104) Plus Lenvatinib in Patients With Advanced Endometrial CancerActive, not recruitingNCT05824481Phase 2Report a problem
- Zimberelimab Plus Lenvatinib After Progression on Prior Immune Checkpoint Inhibitors for Advanced Cervical CancerActive, not recruitingNCT05824468Phase 2Report a problem
- Tislelizumab Monotherapy or Combined With Lenvatinib as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma.CompletedNCT05807776Phase 2Report a problem
- Nivolumab Plus Lenvatinib Against Anaplastic Thyroid Cancer (NAVIGATION)Active, not recruitingNCT05696548Phase 2Report a problem
- HAIC or Lenvatinib Combined With Sintilimab for High Recurrence Risk Resectable Solitary Hepatocellular CarcinomaActive, not recruitingNCT05621499Not applicableReport a problem
- Tislelizumab Combined With Lenvatinib and GEMOX Versus Tislelizumab Combined With GEMOX in Conversion Therapy of ICC and GBC.Status unknownNCT05620498Phase 2Report a problem
- Second-line Treatment With Serplulimab, Lenvatinib, and Paclitaxel in Advanced Gastric Cancer After Prior ImmunotherapyActive, not recruitingNCT05585580Phase 2Report a problem
- Neoadjuvant Pembrolizumab and Lenvatinib for Mucosal MelanomaWithdrawnNCT05545969Phase 2Report a problem
- HAIC Sequential TAE Combined With Lenvatinib and Tislelizumab in Unresectable HCCCompletedNCT05532319Phase 2Report a problem
- Lenvatinib Combined With PD-1 Inhibitors as First-line Treatment for Unresectable/Advanced Biliary Tract CarcinomaStatus unknownNCT05509478Phase 2Report a problem
- Neoadjuvant Therapy of Pembrolizumab Plus Lenvatinib in Advanced RCCCompletedNCT05485896Phase 2Report a problem
- Envafolimab, Lenvatinib Combined With VP-16 in Platinum-resistant Recurrent Epithelial Ovarian CancerStatus unknownNCT05422183Phase 2Report a problem
- Cryoablation Combined With Tislelizumab Plus Lenvatinib in Patients With Melanoma Liver MetastasisStatus unknownNCT05406466Phase 2Report a problem
- Pembrolizumab and Lenvatinib for Resectable Hepatocellular CarcinomaActive, not recruitingNCT05389527Phase 2Report a problem
- Study of Pembrolizumab, Lenvatinib and Chemotherapy Combination in First Line Extensive-stage Small Cell Lung CancerActive, not recruitingNCT05384015Phase 2Report a problem
- An Open-label, Phase I/II Study of PLENA Regimen in Patients With Unresectable Pancreatic Cancer or BTCStatus unknownNCT05327582Phase 1/2Report a problem
- Sequential PD-1/PD-L1 Inhibitor and LENvatinib in TLCT and Refractory Hepatoblastoma After ChemotherapyStatus unknownNCT05322187Phase 2/3Report a problem
- Durvalumab Plus Lenvatinib as First-line Treatment for Unresectable Hepatocellular CarcinomaStatus unknownNCT05312216Phase 2Report a problem
- Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCCActive, not recruitingNCT05301842Phase 3Report a problem
- Pembrolizumab and Lenvatinib in Clear Cell Ovarian CancerActive, not recruitingNCT05296512Phase 2Report a problem
- Tisleizumab Combined With Lenvatinib and XELOX Regimen (Oxaliplatin Combined With Capecitabine) in the First-line Treatment of Advanced and Unresectable Biliary Tract TumorsStatus unknownNCT05291052Phase 2Report a problem
- Phase II Lenvatinib and Pembrolizumab in Endocrine Resistant Breast Cancer With LetrozoleActive, not recruitingNCT05286437Phase 2Report a problem
- Efficacy and Safety of Pembrolizumab in Combination With Lenvatinib in Metastatic Uveal MElanoma Patients (PLUME)CompletedNCT05282901Phase 2Report a problem
- A Pilot Study to Assess Changes in Tumor Biology Following Second-line Treatment With Pembrolizumab Plus Lenvatinib in Patients With Advanced Pancreatic Ductal AdenocarcinomaCompletedNCT05273554Phase 1Report a problem
- Lenvatinib in Combination With Carboplatin Pemetrexed and Pembrolizumab for NSCLC With EGFR MutationsCompletedNCT05258279Phase 2Report a problem
- TACE Combined With "Target Immune" Therapy for First-line Treatment in the Treatment of Intrahepatic CholangiocarcinomaStatus unknownNCT05247996Not applicableReport a problem
- Study on Therapeutic Effect of Combination of Envafolimab, Lenavatinib and TACE in Advanced HCC PatientsCompletedNCT05213221Phase 2Report a problem
- Rapid Sequencing of Approved Therapies in Patients With Metastatic or Unresectable Clear Cell Renal Cell CarcinomaCompletedNCT05188118Early Phase 1Report a problem
- Lenvatinib With Taxane Drugs Treatment for Advanced Gastric CancerStatus unknownNCT05171530Phase 1Report a problem
- Lenvatinib Plus Paclitaxel for Patients With Advanced Biliary Tract Cancer Who Failed to Gemcitabine-based TreatmentActive, not recruitingNCT05170438Phase 2Report a problem
- Tislelizumab(Anti PD-1), Lenvatinib and GEMOX Transformation in the Treatment of Potentially Resectable, Locally Advanced Biliary Tract CancerActive, not recruitingNCT05156788Phase 2Report a problem
- A Study of Pembrolizumab With Lenvatinib in Women With Advanced Uterine CarcinosarcomaActive, not recruitingNCT05147558Phase 2Report a problem
- Clinical Study of the Efficacy and Safety of Transhepatic Arterial Chemoembolization Combined With Tislelizumab and Lenvatinib in Patients With Advanced Unresectable Hepatocellular CarcinomaStatus unknownNCT05131698Early Phase 1Report a problem
- Pembrolizumab and Lenvatinib for the Treatment of Serous Ovarian Cancer PatientsActive, not recruitingNCT05114421Phase 2Report a problem
- Pembrolizumab and Lenvatinib in Patients With Advanced HCC Who Are Refractory to Atezolizumab and Bevacizumab/ IO-based TherapyCompletedNCT05101629Phase 2Report a problem
- A Study to Evaluate Pembrolizumab Plus Lenvatinib in PD-L1 Positive TKI Resistant NSCLC PatientsActive, not recruitingNCT05078931Phase 2Report a problem
- The Effectiveness and Safety of Camrelizumab/Lenvatinib Combined With TACE in Patients With Borderline Resectable HCCStatus unknownNCT05042336Phase 1/2Report a problem
- Pembrolizumab and Lenvatinib for the Treatment of Advanced, Unresectable, or Metastatic Gastroesophageal AdenocarcinomaActive, not recruitingNCT05041153Early Phase 1Report a problem
- Tislelizumab+Lenvatinib+Gemox Regiment for Potentially Resectable Locally Advanced Malignant Tumors of Biliary System.Status unknownNCT05036798Phase 2Report a problem
- Phase II Trial of Pembrolizumab Plus Lenvatinib in Advanced Adrenal Cortical CarcinomaActive, not recruitingNCT05036434Phase 2Report a problem
- Lenvatinib With Everolimus Versus Cabozantinib for Second-Line or Third-Line Treatment of Metastatic Renal Cell CancerActive, not recruitingNCT05012371Phase 2Report a problem
- Cryoablation Combined with Sintilimab Plus Lenvatinib in Patients with Advanced Intrahepatic CholangiocarcinomaCompletedNCT05010668Phase 2Report a problem
- Hepatic Arterial Infusion Combined With Lenvatinib and Camrelizumab for Unresectable Hepatocellular CarcinomaCompletedNCT05003700Phase 2Report a problem
- The Safety and Efficacy of Transarterial Chemoembolization (TACE) + Lenvatinib + Programmed Cell Death Protein 1 (PD-1) Antibody of Advanced Unresectable Hepatocellular CarcinomaCompletedNCT04997850Phase 1/2Report a problem
- Pembrolizumab, Lenvatinib and Chemotherapy After TKIs in NSCLCStatus unknownNCT04989322Phase 2Report a problem
- PD-1 Antibody and Lenvatinib Plus TACE on Downstaging BCLC B/C HCCStatus unknownNCT04974281Early Phase 1Report a problem
- The Efficacy of Hepatic Arterial Infusion Chemotherapy (HAIC) Combine Lenvatinib and Durvalumab (HILL) in Advanced Hepatocellular Carcinoma (HCC)Status unknownNCT04961918Phase 2Report a problem
- The Efficacy and Safety of TACE, Lenvatinib and Camrelizumab in the Treatment of BCLC Stage B/C Hepatocellular Carcinoma: a Single-arm, Single-center, Open-label StudyStatus unknownNCT04909866Phase 2/3Report a problem
- Lenvatinib and Pembrolizumab Maintenance Therapy for the Treatment of Patients of Advanced Unresectable Pancreatic CancerActive, not recruitingNCT04887805Phase 2Report a problem
- Trial Exploring Combined Neoadjuvant Therapy With Pembrolizumab/Lenvatinib + Adjuvant Pembrolizumab in Pat. With NSCLCActive, not recruitingNCT04875585Phase 2Report a problem
- Tislelizumab Combined With Lenvatinib for Perioperative Treatment of Resectable Primary Hepatocellular CarcinomaStatus unknownNCT04834986Phase 2Report a problem
- PD-1 Antibody and Lenvatinib Plus TACE-HAIC for Potential Resectable HCC: a Single-arm, Phase 2 Clinical TrialStatus unknownNCT04814043Phase 2Report a problem
- Lenvatinib and Pembrolizumab in People With Advanced Soft Tissue SarcomaActive, not recruitingNCT04784247Phase 2Report a problem
- Systemic Chemotherapy, Lenvatinib Plus Sintilimab for ICC With Distant MetastasisStatus unknownNCT04769908Phase 2Report a problem
- An Open Label Phase 2 Study to Evaluate the Safety and Efficacy of Lenvatinib With Pembrolizumab or Lenvatinib, Pembrolizumab and FLOT in the Neoadjuvant / Adjuvant Treatment for Patients With Gastric CancerActive, not recruitingNCT04745988Phase 2Report a problem
- Pembrolizumab and Lenvatinib/Chemotherapy for Poorly Differentiated/Anaplastic Thyroid CancerWithdrawnNCT04731740Phase 2Report a problem
- Pembrolizumab And Lenvatinib In Leptomeningeal MetastasesTerminatedNCT04729348Phase 2Report a problem
- Combination of Pembrolizumab and Lenvatinib, in Pre-treated Thymic CArcinoma paTIentsCompletedNCT04710628Phase 2Report a problem
- Trial of Lenvatinib Plus PembrolizumAb in Recurrent Gynecological Clear Cell Adenocarcinomas (LARA)Status unknownNCT04699071Phase 2Report a problem
- Phase II-III Clinical Trial of PD1 Antibody (Toripalimab), Lenvatinib and GEMOX Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence FactorsActive, not recruitingNCT04669496Phase 2/3Report a problem
- Lenvatinib and Pembrolizumab in Resectable Mucosal MelanomaStatus unknownNCT04622566Phase 2Report a problem
- HAIC Combined With Lenvatinib and Sintilimab for Hepatocellular Carcinoma With PVTTCompletedNCT04618367Not applicableReport a problem
- TACE Combined With Lenvatinib and Sintilimab for Advanced HCCCompletedNCT04599790Phase 2Report a problem
- Pembrolizumab in Combination With Lenvatinib in Patients With Advanced Biliary Tract CarcinomaCompletedNCT04550624Phase 2Report a problem
- Cisplatin and Gemcitabine Chemotherapy and Lenvatinib for Patients With Unresectable Intrahepatic CholangiocarcinomaStatus unknownNCT04527679Phase 2Report a problem
- PD1 Antibody (Toripalimab), GEMOX and Lenvatinib Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence FactorsStatus unknownNCT04506281Phase 2Report a problem
- Durvalumab and Lenvatinib in Participants With Advanced and Recurrent Endometrial CarcinomaStatus unknownNCT04444193Not applicableReport a problem
- Lenvatinib in Combination With Camrelizumab as First-Line Therapy in Patients With Advanced HCCStatus unknownNCT04443309Phase 1/2Report a problem
- Preoperative Lenvatinib Plus Pembrolizumab in Early-Stage Triple-Negative Breast Cancer (TNBC)Active, not recruitingNCT04427293Phase 1Report a problem
- Pembrolizumab and LENvatinib in Participants With Hepatocellular Carcinoma (HCC) Before Liver TransplantStatus unknownNCT04425226Not applicableReport a problem
- Lenvatinib Combined Toripalimab in Advanced Hepatocellular CarcinomaStatus unknownNCT04368078Phase 2Report a problem
- Two-cohort Study of Toripalimab(PD1)+Lenvatnib, or Gemox+Lenvatinib in Advanced Intrahepatic CholangiocarcinomaCompletedNCT04361331Phase 2Report a problem
- Substudy 02B: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With First Line (1L) Advanced Melanoma (MK-3475-02B/KEYMAKER-U02)CompletedNCT04305054Phase 1/2Report a problem
- Pembrolizumab Plus Lenvatinib In Second Line and Third Line Malignant Pleural mesotheLioma PatientsActive, not recruitingNCT04287829Phase 2Report a problem
- PD-1 Monoclonal Antibody, Lenvatinib and TACE in the Treatment of HCCStatus unknownNCT04273100Phase 2Report a problem
- Relenvatinib in the Tatment of Recurrence of Hepatocellular Carcinoma After Liver TransplantationStatus unknownNCT04237740Phase 3Report a problem
- DEB-TACE Plus Lenvatinib or Sorafenib or PD-1 Inhibitor for Unresectable Hepatocellular CarcinomaStatus unknownNCT04229355Phase 3Report a problem
- Toripalimab Plus Lenvatinib as Second-line Treatment in Advanced Biliary Tract CancersStatus unknownNCT04211168Phase 2Report a problem
- Lenvatinib and Pembrolizumab in People With Advanced Adenoid Cystic Carcinoma and Other Salivary Gland CancersActive, not recruitingNCT04209660Phase 2Report a problem
- A Phase II Study of Neoadjuvant Pembrolizumab & Lenvatinib for Resectable Stage III MelanomaActive, not recruitingNCT04207086Phase 2Report a problem
- Lenvatinib and Pembrolizumab for the Treatment of Stage IVB Locally Advanced and Unresectable or Stage IVC Metastatic Anaplastic Thyroid CancerActive, not recruitingNCT04171622Phase 2Report a problem
- Systemic Chemotherapy Plus Lenvatinib and Toripalimab for HCC With Extrahepatic MetastasisStatus unknownNCT04170179Phase 2Report a problem
- HAIC Plus Lenvatinib and Toripalimab for Advanced HCCCompletedNCT04044313Phase 2Report a problem
- Sintilimab Combined With Lenvatinib in Local Advanced Hepatocellular CarcinomaStatus unknownNCT04042805Phase 2Report a problem
- Combined Therapy Using Oxaliplatin and Gemcitabine Chemotherapy, Lenvatinib and PD1 Antibody (JS001) for Patients With Advanced and Unresectable Intrahepatic CholangiocarcinomaStatus unknownNCT03951597Phase 2Report a problem
- Lenvatinib and Everolimus in Treating Patients With Advanced, Unresectable Carcinoid TumorsActive, not recruitingNCT03950609Phase 2Report a problem
- Phase II of Lenvatinib Plus Toripalimab for Advanced HCCWithdrawnNCT03919383Phase 2Report a problem
- Lenvatinib Combined Pembrolizumab in Advanced Hepatobiliary TumorsCompletedNCT03895970Phase 2Report a problem
- Immunotherapy With Nivolumab in Combination With Lenvatinib for Advanced Stage Hepatocellular CarcinomaCompletedNCT03841201Phase 2Report a problem
- Lenvatinib Plus PD-1 Antibody vs TACE for Intermediate-stage HCC Beyond Up-to-seven CriteriaWithdrawnNCT03791918Phase 3Report a problem
- Lenvatinib Plus PD-1 Antibody for Unresectable ICCSuspendedNCT03779100Phase 2Report a problem
- Lenvatinib Plus PD-1 Antibody for Intermediate-stage HCC Beyond Up-to-seven CriteriaWithdrawnNCT03775707Phase 2Report a problem
- Phase II of Lenvatinib Plus PD-1 Antibody for Advanced HCCWithdrawnNCT03746249Phase 2Report a problem
- Study of the Efficacy of Lenvatinib Combined With Denosumab in the Treatment of Patients With Predominant Bone Metastatic Radioiodine Refractory Differentiated Thyroid CarcinomasStatus unknownNCT03732495Phase 2Report a problem
- Lenvatinib and Everolimus in Renal Cell Carcinoma (RCC)CompletedNCT03324373Phase 1Report a problem